Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. (Canceled)

12. (Currently Amended) A method for treating ~~or preventing~~ a ~~major~~ treatment resistant depression ~~and/or treating a wake-sleep cycle disorder~~, comprising

administering to a subject in need thereof a pharmaceutical composition comprising a compound with formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein the hydrogen atom in position 3 and the hydrogen atom in position 16 are trans, and the hydroxyl radical in position 14 in an α or β form.

13-15. (Canceled)

16. (Currently Amended) The method of claim 12, wherein the subject is suffering from [[the]] a major depression and is resistant to a classical antidepressant treatment and wherein said administering makes the subject sensitive to the classical antidepressant treatment.

17. (Canceled)

18. (Previously Presented) The method of claim 12, wherein the compound with formula (I) or one of its pharmaceutically acceptable salts is in the form of a racemic or an optically active mix.

19. (Previously Presented) The method of claim 12, wherein the compound with formula (I) or one of its pharmaceutically acceptable salts is selected from:

a) (3α) (±) 14,15-dihydro 20,21-dinoreburnamenin 14-ol; and

b) (16α) (±) 14,15-dihydro 20,21-dinoreburnamenin 14-ol,

and wherein (+) and (-) diastereoisomers are or are not present in the compound in an equimolar proportion.

20. (Previously Presented) The method of claim 12, wherein the compound with formula (I) or one of its pharmaceutically acceptable salts is selected from the group consisting of

a) (3α, 14α) 14,15-dihydro 20,21-dinoreburnamenin 14-ol;

b) (3α, 14β) 14,15-dihydro 20,21-dinoreburnamenin 14-ol;

c) (14α, 16α) 14,15-dihydro 20,21-dinoreburnamenin 14-ol; and

d) (14β, 16α) 14,15-dihydro 20,21-dinoreburnamenin 14-ol.

21. (Previously Presented) The method of claim 12, wherein said administering is performed orally, intravenously, or by an intraperitoneal or intramuscular method.

22. (Previously Presented) The method of claim 12, wherein said administering comprises administering a daily dose from 20 to 60 mg of the compound with formula (I) or a pharmaceutically acceptable salt thereof.

23. (New) The method of claim 12, wherein said administering results in at least one of the following:

a) an increase of a number of noradrenergic neurons in a locus caerelus of the subject;

b) an increase of a number of hypocretin neurons in a hypothalamus of the subject;

c) an increase of a density of noradrenalin fibers in a prefrontal cortex of the subject; and

d) reactivating a capacity in the subject to display an increased REM sleep after sleep depravation.

24. (New) The method of claim 23, wherein said administering results in the increase of the number of the noradrenergic neurons in the locus coeruleus of the subject.

25. (New) The method of claim 23, wherein said administering results in the increase of the number of the hypocretin neurons in the hypothalamus of the subject.

26. (New) The method of claim 23, wherein said administering results in the increase of the density of noradrenalin fibers in the prefrontal cortex of the subject.

27. (New) The method of claim 23, wherein said administering results in reactivating the capacity in the subject to display an increased REM sleep after sleep depravation.

28. (New) The method of claim 12, wherein said administering results in a) an increase of a number of noradrenergic neurons in a locus caerelus of the subject; b) an increase of a number of hypocretin neurons in a hypothalamus of the subject; c) an increase of a density of noradrenalin fibers in a prefrontal cortex of the subject; and d) reactivating a capacity in the subject to display an increased REM sleep after sleep depravation.